UCB Raises 2026 Revenue Growth Forecast to 20%+ on Bimzelx, Cimzia Strength

UCB lifted its 2026 revenue growth outlook to slightly above 20% at constant exchange rates, up from 10-15%, citing strong US sales of Bimzelx and improved Cimzia volumes and pricing. The revision signals accelerating commercial momentum and improved profitability, though it is company-specific rather than a broad market signal.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works